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Abstract 
Coagulation disorders are common in patients with 
malignancy, sometimes leading to arterial and venous 
thrombosis. Such patients are therefore at increased risk 
for ischaemic stroke. Though usually occurring in 
advanced stages of cancers, sometimes stroke can be the 
first manifestation of a hidden, yet undiagnosed, 
malignancy. In this report, I present a case of recurrent 
strokes secondary to malignancy-related 
thromboembolism in a 63-year old gentleman.   
 
Key Words 
Malignancy, Hypercoagulability, Stroke 
 
Case Presentation 
A 63-year old man presented to A&E department 
with altered mental status. He was found by his wife 
attempting to turn on the switch but being unable to 
locate it with his right hand. He also had dysarthria and 
was somewhat confused. He had a history of type II 
diabetes mellitus, hypertension and dyslipidaemia. 
Moreover, he had suffered an ischaemic stroke 3 months 
previous to this admission affecting the right middle 
cerebral artery territory. His medications included the 
antiplatelet agents aspirin and dipyridamole, the 
hypoglycaemic agent metformin and the HMG-CoA 
reductase inhibitor simvastatin. He had stopped smoking 
15 years previously.  
 
 
 
 
 
 
 
 
 
 
 
 
This patient thus suffered two ischaemic strokes in 
different vascular territories in 3 months and a 
coagulopathy was considered to be the cause. A chest x-
ray revealed a lesion in the right lung base, which was 
confirmed on CT; the latter also detecting right hilar and 
supracarinal lymphadenopathy. CT-guided biopsy of the 
lung lesion was then carried out which showed 
adenocarcinoma of the lung. Right lower lobectomy was 
performed but merely two weeks after surgery, the 
patient presented again with another left-sided stroke; 
the third one in four months. While an in-patient, he also 
had a deep vein thrombosis, despite being anticoagulated 
with enoxaparin. His general condition was very poor 
and he was treated palliatively until he passed away.  
 
Discussion 
The relationship between malignancy and 
hypercoagulability is well known and actually 
thromboembolic events occur in around 11% of patients 
with cancer and account for the second leading cause of 
mortality in cancer.1 Almost all cancers are associated 
with coagulopathy but especially myeloproliferative 
disorders as well as cancers of the pancreas, prostate, 
colon, gallbladder, stomach and lung adenocarcinoma.2 
This association between cancer and 
hypercoagulability was first described by Armand 
Trousseau in 1865, and since then malignancy-
associated thromboembolic disorders have been termed 
Trousseau syndrome.3 Its clinical manifestations include 
arterial thrombosis, recurrent venous thrombosis, non-
bacterial thrombotic endocarditis and disseminated 
intravascular coagulation (DIC) as well as accelerated 
ischaemic heart disease and peripheral vascular 
disease.4-5  
There are various pathogenic mechanisms, which 
explain the hypercoagulable state of malignancy. 
Tumour cells produce pro-coagulant factors like 
interleukin-1, interleukin-6, tumour necrosis factor-1, 
factor X and factor XII.6 Moreover, adenocarcinomas 
produce a lot of mucin; high molecular weight, heavily 
glycosylated proteins that result in platelet-rich 
microthrombi.7-8  
Malignancy can result in hypercoagulability in a 
variety of other ways. Some chemotherapeutic agents 
like mitomycin and some hormonal agents like 
tamoxifen are prothrombotic.9-10 Trauma, as a result of 
surgery, can also play an important role by exposing 
subendothelial tissue factor, activating the extrinsic 
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coagulation pathway. Decreased mobility is also another 
risk factor.  
Cancer patients with thromboembolic disease often 
have biochemical evidence of an activated coagulation 
cascade. Many have thrombocytosis, as well as high PT 
and APTT, and elevated levels of fibrinogen and D-
dimers. However, since cancer can cause deranged 
clotting activity and many patients with thrombosis have 
normal levels of these markers, studies have shown that 
they are clinically neither specific nor sensitive to 
malignancy-associated thromboembolism.11-12 
Although cerebrovascular events are quite frequent 
in cancer patients, stroke as the first manifestation of 
cancer, as happened in this case, is uncommonly 
reported.13 When presented with multiple bihemispheric 
infarctions on diffusion-weighted imaging, early relapse 
or anaemia, one must consider the possibility of an 
occult cancer. In their study, Hiraga and colleagues 
claimed that the commonest cancer in stroke patients in 
the West is lung cancer, followed by gastrointestinal 
cancer. They recommend that a proper cancer work-up 
should be done in cases where the aetiology of stroke is 
unknown or where there are recurrent strokes and 
systemic thromboses, including thoracic imaging and 
measurement of tumour markers like CEA and 
CA19.9.14  
The prognosis of patients with malignancy-
associated thromboembolism is poor and management is 
very difficult. Recurrent arterial and venous thromboses 
mean that these patients should be on long-term 
anticoagulation. However warfarin is not a very good 
choice in these patients because of its narrow therapeutic 
window, need for frequent monitoring and tendency to 
interact with numerous other drugs. In a randomized 
controlled trial, Lee and colleagues compared warfarin 
against heparin in patients with active cancer and a 
confirmed DVT/PE. They found that fewer patients on 
heparin had recurrent venous thrombosis and the 
mortality rate was also less. On the other hand, there was 
no statistically significant difference in the rate of 
bleeding.15 Recent studies have also shown a trend 
towards decreased mortality with low-molecular-weight 
heparin as compared to unfractionated heparin.16-17  
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